Yudith Setiati Ermaya

Dr. Yudith Setiati Ermaya

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2025 in Medicina
Verified
Journal Article
Open access
PDF file
DPDwi Prasetyo
Dwi Prasetyo
YEYudith Setiati Ermaya
Yudith Setiati Ermaya
GHGustavo Hernandez-Suarez
Gustavo Hernandez-Suarez
AGAdriana Guzman-Holst
Adriana Guzman-Holst
CKCissy B. Rachiana Kartasasmita
Cissy B. Rachiana Kartasasmita
Background and Objectives: Hepatitis A is an infectious disease caused by the hepatitis A virus (HAV), which is transmitted via the fecal–oral route, either through the consumption of contaminated food and water or through direct contact with an infected individual. The incidence of HAV is closely associated with socioeconomic factors, access to clean drinking water, sanitation safety, and hygiene. This study aimed to determine HAV seroprevalence and shifting endemicities of hepatitis A virus infection. The seroprevalence and endemicity status were assessed based on the age at the midpoint of population immunity (AMPI). Materials and Methods: A cross-sectional seroprevalence study was conducted in two contrasting areas (urban vs. rural) in Bandung, Indonesia. All participants underwent serological testing for anti-HAV IgG using a chemiluminescent microparticle immunoassay (CMIA) and participated in questionnaire interviews. Socioeconomic status was assessed using the Water/sanitation, Assets, Maternal education, and Income (WAMI) index. All statistical analyses were performed using SPSS 18, with a p-value of <0.05 considered significant. Results: A total of 1280 participants were tested (640 living in urban areas; 640 living in rural areas). The total prevalence of HAV seropositivity was 50.5% (95% confidence interval [CI]: 47.7–53.3%), with prevalences of 46.1% (95% CI: 42.5–54.4%) across urban sites and 54.7% (95% CI: 50.7–58.6%) across rural sites. The AMPI was within the 20–24-year age group, with an age point of 22 years, classified as an intermediate HAV endemicity status. Conclusions: the study found a shift in HAV endemicity status from low to intermediate, supporting the need for large-scale national hepatitis A vaccination in Indonesia.

18 March 2025 in BMC Pediatrics
Verified
Journal Article
Open access
YEYudith Setiati Ermaya
Yudith Setiati Ermaya
ENEka Surya Nugraha
Eka Surya Nugraha
DGDolvy Girawan
Dolvy Girawan
NRNelly Amalia Risan
Nelly Amalia Risan
MBMuhammad Begawan Bestari
Muhammad Begawan Bestari
DPDwi Prasetyo
Dwi Prasetyo
Background: Hepatitis B Virus infection is a global health problem. Transplacental maternal antibodies can protect the infant early in life from infection. Objectives: This study investigates the correlation between maternal and infant Hepatitis B surface antibodies (anti-HBs) in pairs. Methods: This cross-sectional study measured anti-HBs in paired mother-infant samples. Blood samples were taken from the mother 3 h before delivery and from the newborn immediately after birth by cord blood, and they were then examined for anti-HBs using the Chemiluminescent Microparticle Immunoassay. Results: Transplacental transfer of maternal anti-HBs was analyzed in 79 mother-infant pairs. Seventeen mothers (21.5%) had positive anti-HBs and all cord blood of newborns from these mothers had anti-HBs detected. Overall, there were 44 (55.7%) newborn blood cords that were positive for anti-HBs. The geometric mean of anti-HBs cord blood titers in newborns with maternal anti-HBs titers < 10, ≥10, ≥ 100, and ≥ 1,000 mIU/mL were 52.42, 193.83, 437.12, and ≥ 1,000 mIU /mL respectively. This study showed a significant correlation in anti-HBs between mother and infant cord blood (r = 0.863; p < 0,001). Conclusions: Anti-HB antibodies measured in mother and infant cord blood were strongly correlated, demonstrating efficient transplacental antibody transfer to protect infants against Hepatitis B infection. Hepatitis B vaccination is required for mothers to obtain immunogenicity and babies to receive hepatitis B vaccination on time.

17 October 2025 in Children
Verified
Journal Article
Open access
PDF file
YEYudith Setiati Ermaya
Yudith Setiati Ermaya
YSYunia Sribudiani
Yunia Sribudiani
RGReni Ghrahani
Reni Ghrahani
SQSeng Hock Quak
Seng Hock Quak
DPDwi Prasetyo
Dwi Prasetyo
Background: Despite the widespread implementation of Hepatitis B vaccination, some children fail to develop protective immunity. Thus, identifying markers for vaccine unresponsiveness is crucial for optimizing current strategies. As interleukin-12 (IL-12), a central cytokine in Th 1 immune activation, has shown potential as a predictive biomarker, the aim of this study was to determine its role in the Hepatitis B vaccine response, highlighting novel findings regarding the threshold level of IL-12 in the pediatric population in doing so. Methods: A cross-sectional study was conducted on a community in Bandung City. The subjects were 7–12-month-old babies who had completed primary Hepatitis B vaccination (0, 2, 3, and 4 months of age). Blood tests for anti-HB examination were performed with a Chemiluminescent Microparticle Immunoassay (CMIA) to determine the response and non-response groups, and an Enzyme Immunosorbent Assay (ELISA) was used for IL-12 detection. Data were analyzed using the Kruskal–Wallis test, Chi-square test, Spearman Correlation, and Receiver Operating Characteristics. Statistical analysis was conducted with SPSS version 18.0. Results: The results of this study indicate that 4.5% of the subjects were unresponsive to the Hepatitis B vaccine. The most important finding was a significant correlation between IL-12 and the presence of anti-HB titers in the responsive and non-responsive groups (p = 0.016). The Receiver Operating Characteristics (ROC) curve for IL-12 identified a cut-off point of ≥10.65 pg/mL (>100 mIU/mL in anti-HBs), with a sensitivity of 64.23%, specificity of 68.75%, and accuracy of 65.2%. Conclusions: Interleukin-12 can be considered as an early candidate biomarker for responsiveness to the Hepatitis B vaccine in children.